1,200 articles
Johannes Zuber
Johannes Zuber, born 1974 in Dresden, is an Austrian-based molecular biologist and Senior Group Leader at the Research Institute of Molecular Pathology in Vienna, studying cancer dependencies through functional genomics.
John A. Baron
John A. Baron is an American physician and clinical epidemiologist known for randomized chemoprevention trials in colorectal cancer prevention, including the Calcium Polyp Prevention Study, and professor emeritus at Dartmouth.
John B.A.G. Haanen
John B.A.G. Haanen, also known as John B. Haanen, is a Dutch medical oncologist who leads immunotherapy at the Netherlands Cancer Institute and won the 2024 ESMO Lifetime Achievement Award.
John Bridgewater
John Bridgewater (John A. Bridgewater) is a British medical oncologist and Clinical Professor at the UCL Cancer Institute, known for the ABC-02 and BILCAP trials defining biliary tract cancer treatment.
John Brognard
John Brognard is an American cancer pharmacologist who studies kinase signaling networks in lung, head and neck, and breast cancers, winning a Presidential Early Career Award in 2017.
John C. Byrd
John C. Byrd is an American physician-scientist in hematologic malignancies who directs UPMC Hillman Cancer Center and led development of the leukemia drugs ibrutinib and acalabrutinib.
John Crown
John Crown is an Irish medical oncologist at St Vincent's University Hospital, Dublin, known for breast cancer drug trials and for founding the national trials group ICORG, now Cancer Trials Ireland.
John D. Hainsworth
John D. Hainsworth is an American medical oncologist in Nashville who co-founded the Sarah Cannon Research Institute in 1993 and directs clinical research at Sarah Cannon Cancer Center.
John D. Minna
John D. Minna is an American medical oncologist and lung cancer researcher who directs the Hamon Center for Therapeutic Oncology Research at UT Southwestern in Dallas.
John D. Schuetz
John D. Schuetz is an American pharmacologist and oncology researcher at St. Jude Children's Research Hospital in Memphis, known for work on ABC transporters in chemotherapy response.
John David Carpten
John David Carpten is an American cancer geneticist, director of City of Hope's Comprehensive Cancer Center, known for discovering the first hereditary prostate cancer gene, HOXB13.
John Dick (cancer researcher)
John Dick is a Canadian cancer researcher at the Princess Margaret Cancer Centre in Toronto who showed in 1994 that leukemia is sustained by rare self-renewing stem cells.
John E. Dick
John E. Dick is a Canadian cancer stem cell biologist at the Princess Margaret Cancer Centre in Toronto who first identified leukemia stem cells in acute myeloid leukemia.
John E. Niederhuber
John E. Niederhuber is an American surgical oncologist who served as the 13th director of the National Cancer Institute from 2006 to 2010 and pioneered implantable chemotherapy devices.
John H. Kersey
John H. Kersey (1938–2013) was an American physician-scientist in pediatric hematology-oncology at the University of Minnesota; in 1975 he led the world's first successful bone marrow transplant for lymphoma.
John Joseph Bittner
John Joseph Bittner (1904–1961) was an American geneticist who discovered the "milk factor", an agent in mother's milk transmitting mammary cancer in mice, later called mouse mammary tumor virus.
John L. Cleveland
John L. Cleveland is an American cancer biologist and Center Director of Moffitt Cancer Center in Tampa, known for research on the MYC oncogene and Myc-driven lymphoma.
John L. Ziegler
John L. Ziegler, born 1938, is an American oncologist and UCSF professor emeritus who developed curative chemotherapy for Burkitt's lymphoma in Uganda and won the 1972 Lasker Award.
John M. Kirkwood
John M. Kirkwood is an American oncologist and melanoma researcher at the University of Pittsburgh, whose trials established the first effective adjuvant therapy for high-risk melanoma.
John M. Maris
John M. Maris is an American pediatric oncologist at the Children's Hospital of Philadelphia whose laboratory discovered the genetic basis of the childhood cancer neuroblastoma, including the ALK gene.
John Mendelsohn (oncologist)
John Mendelsohn (1936–2019) was an American molecular biologist and oncologist whose research founded anti-EGFR targeted cancer therapies and who served as president of MD Anderson from 1996 to 2011.
John P. Neoptolemos
John P. Neoptolemos is a pancreatic cancer surgeon-scientist, Professor of Surgery at Heidelberg since 2017 and formerly Liverpool's Chair of Surgery, known for the ESPAC adjuvant chemotherapy trials and founding the ISGPS.
John Radford (medical oncologist)
John Radford is a British medical oncologist specializing in lymphoma, Professor at the University of Manchester and Director of Research at The Christie, known for PET-directed Hodgkin lymphoma therapy.
John Simes
John Simes, whose full name is Robert John Simes, is an Australian medical oncologist who founded the NHMRC Clinical Trials Centre in Sydney in 1988.
John T. Lis
John T. Lis is an American molecular biologist at Cornell University, elected to the National Academy of Sciences in 2015, known for discovering that RNA polymerase II pauses near gene promoters.
John V. Heymach
John V. Heymach is an American physician-scientist who chairs Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center, where he led the AEGEAN durvalumab trial and the zongertinib trials.
John Zalcberg
John Raymond Zalcberg AO is an Australian medical oncologist at Alfred Health in Melbourne who co-founded the Australasian Gastrointestinal Trials Group and co-authored a landmark 2008 cetuximab study.
Jolieke G van Oosterwijk
Jolieke G. van Oosterwijk is a Dutch-trained scientist in bone tumor biology known for co-discovering the somatic mosaic genetic basis of Ollier disease and Maffucci syndrome.
Jonas Bergh
Jonas Bergh, full name Carl Jonas Stensson Bergh, is a Swedish clinical cancer researcher and Senior Professor at Karolinska Institutet known for individually tailored breast cancer treatment.
Jonathan A. Ledermann
Jonathan A. Ledermann, also published as Jonathan Ledermann, is a British medical oncologist at UCL specializing in ovarian cancer, known for the 2012 olaparib maintenance trial.